Linked Life Data

21810947

Source:http://linkedlifedata.com/resource/pubmed/id/21810947

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2011-9-22
pubmed:abstractText
Existing monotherapies for the treatment of obesity provide only modest weight loss and/or have adverse side effects, and this is also the case with the cannabinoid receptor 1 (CB1) inverse agonist, rimonabant. We aimed to investigate the possibility of improving efficacy and reducing side effects of rimonabant by cotreatment with opioid system antagonists. Using both genetic and pharmacological removal of opioid signaling in mice, we investigated changes in body weight, food intake, and fat mass as well as behavioral outcomes of interactions between opioid ligands and the CB1 using the inverse agonist, rimonabant. The ability of rimonabant to reduce weight is enhanced by removal of with ?-opioid receptor signaling, while not being greatly affected by ?-opioid receptor blockade. Additionally, lack of opioid signaling, especially ?-opioid receptor, attenuated the ability of rimonabant to decrease immobility time in the Porsolt forced-swim test, a preclinical model of depression. These results indicate that the endogenous opioid system is involved in modulating both the metabolic and mood effects of rimonabant.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1945-7170
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
152
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3661-7
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
CNS opioid signaling separates cannabinoid receptor 1-mediated effects on body weight and mood-related behavior in mice.
pubmed:affiliation
Metabolic Diseases Institute, University of Cincinnati, Cincinnati, Ohio 45237, USA.
pubmed:publicationType
Journal Article